PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
23989533-5	2014	Tecadenoson was administered alone (Dose Period 1) and in combination (Dose Period 2) with esmolol (100 mug/kg/min for 10 min then 50 mug/kg/min for 50 min).	tecadenoson	0-11	period circadian regulator 2	Homo sapiens	76-84
23388705-5	2013	Pretreatment of mice with a phosphorylated prodrug of nitrobenzylmercaptopurine riboside, an inhibitor of mENT1, significantly decreased brain exposure to tecadenoson compared with that of the untreated (control) group, suggesting involvement of mENT1 in transport of tecadenoson across the blood-brain barrier (BBB).	tecadenoson	155-166	solute carrier family 29 (nucleoside transporters), member 1	Mus musculus	106-111
23388705-5	2013	Pretreatment of mice with a phosphorylated prodrug of nitrobenzylmercaptopurine riboside, an inhibitor of mENT1, significantly decreased brain exposure to tecadenoson compared with that of the untreated (control) group, suggesting involvement of mENT1 in transport of tecadenoson across the blood-brain barrier (BBB).	tecadenoson	155-166	solute carrier family 29 (nucleoside transporters), member 1	Mus musculus	246-251
23388705-5	2013	Pretreatment of mice with a phosphorylated prodrug of nitrobenzylmercaptopurine riboside, an inhibitor of mENT1, significantly decreased brain exposure to tecadenoson compared with that of the untreated (control) group, suggesting involvement of mENT1 in transport of tecadenoson across the blood-brain barrier (BBB).	tecadenoson	268-279	solute carrier family 29 (nucleoside transporters), member 1	Mus musculus	106-111
23388705-6	2013	In summary, ENT1 was shown to mediate the transport of tecadenoson in vitro with recombinant and native human protein and in vivo with mice.	tecadenoson	55-66	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	12-16
23388705-7	2013	The micromolar apparent Km value of tecadenoson for transport by native hENT1 in cultured cells suggests that hENT1 will not be saturated at clinically relevant (i.e., nanomolar) concentrations of tecadenoson, and that hENT1-mediated passage across the BBB may contribute to the adverse CNS effects observed in clinical trials.	tecadenoson	36-47	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	72-77
23388705-7	2013	The micromolar apparent Km value of tecadenoson for transport by native hENT1 in cultured cells suggests that hENT1 will not be saturated at clinically relevant (i.e., nanomolar) concentrations of tecadenoson, and that hENT1-mediated passage across the BBB may contribute to the adverse CNS effects observed in clinical trials.	tecadenoson	36-47	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	110-115
23388705-7	2013	The micromolar apparent Km value of tecadenoson for transport by native hENT1 in cultured cells suggests that hENT1 will not be saturated at clinically relevant (i.e., nanomolar) concentrations of tecadenoson, and that hENT1-mediated passage across the BBB may contribute to the adverse CNS effects observed in clinical trials.	tecadenoson	36-47	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	110-115